Researchers sought to determine the safety and efficacy of treatment with long-acting cabotegravir plus rilpivirine in patients with HIV coinfected with asymptomatic hepatitis c virus.
Researchers conducted a modeling study to determine the projected long-term impact of the COVID-19 pandemic on outcomes associated with hepatitis C virus care.
Investigators assessed the factors associated with medication treatment for opioid use disorder and whether it is linked to hepatic decompensation or death in patients with cirrhosis and active opioid use disorder.
Researchers conducted a study that compared rapid treatment with a 7-day course of sofosbuvir-velpatasvir with usual compare in patients with hepatitis C virus infection who use injectable drugs.
Based on a mathematical model, investigators evaluated improvements to the care cascade for people with hepatitis C virus who inject drugs.
Researchers summarized the reciprocal interaction between sleep and liver diseases, including cirrhosis, and investigated potential approaches for therapeutic interventions.
Researchers conducted a cross-sectional study to assess the impact of subscription-based payment models on the rate of prescription fills for hepatitis C virus medications among individuals in Louisiana and Washington enrolled in Medicaid.
Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease
In this phase 4 non-inferiority trial, researchers compared the effects of short course vs standard course therapy with sofosbuvir-velpatasvir for the treatment of patients with hepatitis C virus.
Investigators assessed the safety profile and antiviral activity of the agent RO7049389 for the treatment of chronic hepatitis B virus infection.
The phase 2 trial was evaluating the effects of ABI-H2158 in 88 treatment-naïve patients with HBeAg positive or HBeAg negative chronic hepatitis B infection without cirrhosis.
Investigators reported on the hepatitis C virus cascade of care throughout the first few years of a treatment-as-prevention program initiated in Iceland.
The new vial sizes are currently in stock and commercially available in the US.
Researchers used real-world data to determine the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir treatment in an Asian population with hepatitis C virus infection.
Investigators assessed factors affecting HBsAg seroclearance in individuals with hepatitis B virus infection.
Researchers assessed the cost-effectiveness of universal adult screening for chronic hepatitis B virus infection.
Investigators assessed the effectiveness of hepatitis C virus treatment-as-prevention in a prison setting.
Investigators assessed the safety and efficacy of apatinib in pretreated hepatocellular carcinoma and its effects on overall survival.
A team of researchers sought to compare the seroprotection rate of a hepatitis B virus tri-antigenic vaccine with that of a mono-antigenic vaccine in adults.
The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.